Skip to main content
Equibles

NGEN · Nervgen Pharma Corp. · Metrics

Track NGEN — free

Use NGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.63 +0.28 (+20.74%) At close · Nov 12
Rebalance outlook locked
Market Cap
$175.26M
Shares
107.52M
Volume · Nov 12 2.64M Avg daily vol (3M) 543.25K

NGEN metrics

45 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.63
Market cap
$175.26M

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-17.2%
Price change (3M)
-23.3%
Price change (6M)
-62.9%
Price change (YTD)
-75.9%
Price change (1Y)
-44.1%
Trailing year
Price change (5Y)
-42.1%
52-week high
$5.97
52-week low
$1.32
Change from 52-week high
-77.4%
Change from 52-week low
+2.3%
Annualized volatility
83.1%
Annualized volatility (3M)
57.0%
Implied volatility (30D)
123.2%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.7
RSI (14D)
35.7
Price vs SMA 50
-23.3%
Price vs SMA 200
-49.8%
Avg volume (3M)
508,666
Relative volume
0.5
Average dollar volume
$946,457

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
107.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
33.8
reciprocal yield 3.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.07

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-749.9%
Return on assets
-190.5%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$16.10M
Total assets
$16.93M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
62
13F filer change QoQ
+17
Institutional ownership
11.4%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+607.9%
Holder tenure
1.2
Price vs estimated holder cost
-37.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
4.5%
Latest settlement · 11.2 days to cover
Days to cover
11.2d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1751912 CUSIP 64082X203 13F (30d) 36 filings 36 filers Visit website Investor relations